The expression of CXCR3 and other chemokine receptors on malignant cells is well documented, and their biological behavior in tumor immunity is quite complex and influenced by a variety of factors, including the type of chemokine receptor splice variants, the type of cells in which they are expressed, and the TME. This evidence concerns the gene CXCR3 and neoplasm.